Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension (Q26826864)

main subject

arterial hypertension

1 reference

1 reference

angiogenesis inhibitor

1 reference

B. Nazer

1

1 reference

B. D. Humphreys

series ordinal

2

1 reference

J. Moslehi

series ordinal

3

1 reference

language of work or name

1 reference

11 October 2011

1 reference

1 reference

124

1 reference

issue

15

1 reference

page(s)

1687-91

1 reference

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

cites work

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

VEGF receptor signalling - in control of vascular function

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Home blood-pressure monitoring in patients receiving sunitinib

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

1 reference

7 January 2021

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Management of hypertension in angiogenesis inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Preeclampsia and angiogenic imbalance

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor

1 reference

https://api.crossref.org/works/10.1161%2FCIRCULATIONAHA.110.992230

7 January 2021